- Home
- VRCA vs DHIL Comparison
VRCA vs DHIL Comparison
Compare VRCA & DHIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VRCA | DHIL |
|---|---|---|
| Founded | 2013 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 319.2M |
| IPO Year | 2018 | 1995 |
Fundamental Metrics
Financial Performance| Metric | VRCA | DHIL |
|---|---|---|
| Price | $8.38 | $169.56 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | ★ 415.7K | 49.1K |
| Earning Date | 11-14-2025 | 10-30-2025 |
| Dividend Yield | N/A | ★ 3.54% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 17.21 |
| Revenue | $30,829,000.00 | ★ $149,665,296.00 |
| Revenue This Year | $373.65 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.86 |
| Revenue Growth | ★ 234.73 | 2.65 |
| 52 Week Low | $3.28 | $114.11 |
| 52 Week High | $9.82 | $171.43 |
Technical Indicators
Market Signals| Indicator | VRCA | DHIL |
|---|---|---|
| Relative Strength Index (RSI) | 61.41 | 81.12 |
| Support Level | $7.75 | $168.29 |
| Resistance Level | $9.03 | $171.00 |
| Average True Range (ATR) | 1.02 | 1.63 |
| MACD | -0.12 | 3.22 |
| Stochastic Oscillator | 46.69 | 96.98 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About DHIL Diamond Hill Investment Group Inc.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.